'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects

Journal of Cardiovascular Pharmacology

Volumn 36, Issue 5 SUPPL. 1, 2000, Pages

  Chiou, W J ^a   Wessale, J L ^a   Von Geldern, T ^a   Opgenorth, T J ^a   Wu Wong, J R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 627; Endothelin (ET); Endothelin receptor; Receptor internalization

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; INTERNALIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

EID: 0033761244     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200036001-00119     Document Type: Article

References (10)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Endothelin: New discoveries and rapid progress in the clinic
3. Signal transduction mechanisms mediating the vascular actions of endothelin
4. Cloning and expression of a cDNA encoding an endothelin receptor
5. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
6. Endothelin receptor agonists and antagonists exhibit different dissociation characteristics
7. Endothelin antagonists
8. Pharmacological characterization of A-127722: An orally active and highly potent ET(A)-selective receptor antagonist
9. Pharmacology of A-216546: A highly selective antagonist for the type-A endothelin receptor
10. Endothelin receptor in human astrocytoma U373MG cells: Binding, dissociation, receptor internalization